4.6 Article

Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy

Journal

CANCERS
Volume 14, Issue 22, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14225500

Keywords

caspase-8; CDK9; phospho-CDK9 (Thr 186); prognosis; cervical cancer; radiochemotherapy

Categories

Funding

  1. Deutsche Forschungsgemeinschaft (DFG) [MA 9266/2-1]
  2. German Cancer Aid [70114007]
  3. German Cancer Consortium (DKTK, Heidelberg)

Ask authors/readers for more resources

Elevated levels of caspase-8 and CDK9 are associated with improved outcomes in cervical cancer patients treated with primary platinum-based chemoradiation, while higher levels of phosphorylated CDK9 predict worse survival. Biomarker research can help improve treatment strategies for cervical cancer patients.
Simple Summary Primary concurrent platinum-based chemoradiation (CRT) is the standard-of-care treatment for locally advanced cervical cancer. However, persistent, recurrent or metastatic disease remains a substantial cause of mortality in women worldwide. Biomarker research can help identify the potential mechanisms of chemo- and radioresistance, improve risk stratification and ultimately translate into novel treatment strategies. We report here that elevated pretreatment levels of caspase-8 and cyclin-dependent kinase 9 (CDK9) are associated with significantly improved relapse-free, distant metastasis-free and cancer-specific survival, while, in contrast, higher levels of phosphorylated CDK9 predict an increased risk of recurrence and distant metastases, and inferior cancer-specific survival. Introduction: After primary platinum-based chemoradiation of locally advanced uterine cervical cancer, a substantial proportion of women present with persistent, recurrent or metastatic disease, indicating an unmet need for biomarker development. Methods: We evaluated the clinical records of 69 cervical cancer patients (Federation of Gynecology and Obstetrics, FIGO Stage > IB3) who were subjected to definitive CRT. Immunohistochemical scoring of caspase-8, cyclin dependent kinase 9 (CDK9) and phosphorylated (phospho-)CDK9 (threonine (Thr) 186) was performed on pretreatment samples and correlated with the histopathological and clinical endpoints, including relapse-free survival (RFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS) and overall survival (OS). Results: Lower levels of caspase-8 were more prevalent in patients with a higher T-stage (p = 0.002) and a higher FIGO stage (p = 0.003), and were significantly correlated with CDK9 expression (p = 0.018) and inversely with pCDK9 detection (p = 0.014). Increased caspase-8 levels corresponded to improved RFS (p = 0.005), DMFS (p = 0.038) and CSS (p = 0.017) in the univariate analyses. Low CDK9 expression was associated with worse RFS (p = 0.008), CSS (p = 0.015) and OS (p = 0.007), but not DMFS (p = 0.083), and remained a significant prognosticator for RFS (p = 0.003) and CSS (p = 0.009) in the multivariate analyses. Furthermore, low pCDK9 staining was significantly associated with superior RFS (p = 0.004) and DMFS (p = 0.001), and increased CSS (p = 0.022), and remained significant for these endpoints in the multivariate analyses. Conclusion: Increased caspase-8 and CDK9 levels correlate with improved disease-related outcomes in cervical cancer patients treated with CRT, whereas elevated pCDK9 levels predict worse survival in this patient population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available